Wells Fargo
ALXO icon

Wells Fargo’s ALX Oncology ALXO Stock Holding History

Wells Fargo’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$207K Buy
+99,926
New +$179K ﹤0.01% 5187
2025
Q3 		– Sell
-447
Closed -$186 – 7074
2025
Q2 		$186 Sell
447
-16,014
-97% -$8.08K ﹤0.01% 6445
2025
Q1 		$10.3K Buy
16,461
+362
+2% +$435 ﹤0.01% 5878
2024
Q4 		$26.9K Buy
16,099
+5,603
+53% +$8.61K ﹤0.01% 5683
2024
Q3 		$19.1K Sell
10,496
-79
-0.7% -$294 ﹤0.01% 5653
2024
Q2 		$63.8K Buy
10,575
+1,251
+13% +$15.4K ﹤0.01% 5195
2024
Q1 		$104K Buy
9,324
+1,028
+12% +$14.4K ﹤0.01% 4874
2023
Q4 		$124K Buy
8,296
+2,890
+53% +$27.4K ﹤0.01% 4775
2023
Q3 		$25.9K Sell
5,406
-3,627
-40% -$19.7K ﹤0.01% 5493
2023
Q2 		$67.8K Buy
9,033
+3,928
+77% +$25.7K ﹤0.01% 5259
2023
Q1 		$23.1K Buy
5,105
+3,313
+185% +$25.1K ﹤0.01% 5578
2022
Q4 		$20.2K Buy
1,792
+946
+112% +$10.6K ﹤0.01% 5257
2022
Q3 		$9K Sell
846
-2,718
-76% -$31.7K ﹤0.01% 5710
2022
Q2 		$29K Sell
3,564
-6,889
-66% -$75K ﹤0.01% 5272
2022
Q1 		$177K Sell
10,453
-4,079
-28% -$69.6K ﹤0.01% 5048
2021
Q4 		$312K Buy
14,532
+8,062
+125% +$348K ﹤0.01% 5015
2021
Q3 		$478K Buy
6,470
+5,543
+598% +$369K ﹤0.01% 4684
2021
Q2 		$50K Buy
927
+20
+2% +$1.2K ﹤0.01% 5553
2021
Q1 		$67K Sell
907
-12,556
-93% -$988K ﹤0.01% 5666
2020
Q4 		$1.16M Buy
13,463
+6,205
+85% +$373K ﹤0.01% 3919
2020
Q3 		$274K Buy
+7,258
New +$285K ﹤0.01% 4775

Other funds holding ALXO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Wells Fargo's ALXO Position: Q2 2026 in Review

Wells Fargo opened a new position in ALX Oncology (ALXO) in Q2 2026: 99,926 shares worth $207K. The stake represents ﹤0.01% of the portfolio and ranks #5187 among its holdings. This is a return to the name: Wells Fargo previously reported a position in ALXO as recently as Q2 2025.

Wells Fargo first reported a position in ALXO in Q3 2020 and has held it in 21 quarters since. The position peaked at $1.16M in Q4 2020. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Wells Fargo held 99,926 shares of ALX Oncology worth $207K as of Q2 2026.
  • ALX Oncology was a new Wells Fargo position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5187 holding.
  • Wells Fargo first reported a position in ALX Oncology in Q3 2020 and has held it in 21 quarters since.
  • Wells Fargo's ALX Oncology position peaked at $1.16M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.